Discovery of neddylation E2s inhibitors with therapeutic activity

被引:3
作者
Mamun, M. A. A. [1 ,2 ,3 ,4 ,5 ]
Liu, Ying [1 ,2 ,3 ,4 ,5 ,6 ]
Geng, Yin-Ping [1 ,2 ,3 ,4 ,5 ]
Zheng, Yi-Chao [1 ,2 ,3 ,4 ,5 ]
Gao, Ya [1 ,2 ,3 ,5 ]
Sun, Jian-Gang [7 ]
Zhao, Long-Fei [1 ,2 ,3 ,4 ,5 ]
Zhao, Li-Juan [1 ,2 ,3 ,4 ,5 ,8 ]
Liu, Hong-Min [1 ,2 ,3 ,4 ,5 ]
机构
[1] Minist Educ, Key Lab Adv Drug Preparat Technol, Beijing, Peoples R China
[2] State Key Lab Esophageal Canc Prevent & Treatment, 100 Kexue Ave, Zhengzhou 450001, Peoples R China
[3] Key Lab Henan Prov Drug Qual & Evaluat, 100 Kexue Ave, Zhengzhou 450001, Peoples R China
[4] Inst Drug Discovery & Dev, 100 Kexue Ave, Zhengzhou 450001, Peoples R China
[5] Zhengzhou Univ, Sch Pharmaceut Sci, 100 Kexue Ave, Zhengzhou 450001, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Henan Engn Res Ctr Applicat & Translat Precis Clin, Dept Pharm, Zhengzhou 450052, Peoples R China
[7] Zhengzhou Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Zhengzhou 450052, Henan, Peoples R China
[8] Zhengzhou Univ, Acad Med Sci, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450052, Peoples R China
基金
中国国家自然科学基金;
关键词
NEDD8-ACTIVATING ENZYME; CONJUGATING ENZYMES; C-TERMINUS; E3; LIGASE; UBIQUITIN; NEDD8; PROMOTES; UBIQUITYLATION; PATHWAY; CANCER;
D O I
10.1038/s41389-023-00490-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neddylation is the writing of monomers or polymers of neural precursor cells expressed developmentally down-regulated 8 (NEDD8) to substrate. For neddylation to occur, three enzymes are required: activators (E1), conjugators (E2), and ligators (E3). However, the central role is played by the ubiquitin-conjugating enzymes E2M (UBE2M) and E2F (UBE2F), which are part of the E2 enzyme family. Recent understanding of the structure and mechanism of these two proteins provides insight into their physiological effects on apoptosis, cell cycle arrest and genome stability. To treat cancer, it is therefore appealing to develop novel inhibitors against UBE2M or UBE2F interactions with either E1 or E3. In this evaluation, we summarized the existing understanding of E2 interaction with E1 and E3 and reviewed the prospective of using neddylation E2 as a pharmacological target for evolving new anti-cancer remedies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery
    Jesus Naveja, J.
    Medina-Franco, Jose L.
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (10) : 1059 - 1070
  • [32] Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2
    Ibtisam, Ibtisam
    Kisselev, Alexei F.
    ELIFE, 2024, 12
  • [33] Discovery of 2,4-dimethoxypyridines as novel autophagy inhibitors
    Robke, Lucas
    Rodrigues, Tiago
    Schroeder, Peter
    Foley, Daniel J.
    Bernardes, Goncalo J. L.
    Laraia, Luca
    Waldmann, Herbert
    TETRAHEDRON, 2018, 74 (35) : 4531 - 4537
  • [34] Discovery of piperidinyl aminopyrimidine derivatives as IKK-2 inhibitors
    Kim, Sora
    Jung, Jin Kyo
    Lee, Hyo Seon
    Kim, Youngjae
    Kim, Jiyoon
    Choi, Kihang
    Baek, Du-Jong
    Moon, Bongjin
    Oh, Kwang-Seok
    Lee, Byung Ho
    Shin, Kye Jung
    Pae, Ae Nim
    Nam, Ghilsoo
    Roh, Eun Joo
    Cho, Yong Seo
    Choo, Hyunah
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (10) : 3002 - 3006
  • [35] Transglutaminase 2 inhibitors and their therapeutic role in disease states
    Siegel, Matthew
    Khosla, Chaitan
    PHARMACOLOGY & THERAPEUTICS, 2007, 115 (02) : 232 - 245
  • [36] Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure-activity relationships
    Wenglowsky, Steve
    Ahrendt, Kateri A.
    Buckmelter, Alex J.
    Feng, Bainian
    Gloor, Susan L.
    Gradl, Stefan
    Grina, Jonas
    Hansen, Joshua D.
    Laird, Ellen R.
    Lunghofer, Paul
    Mathieu, Simon
    Moreno, David
    Newhouse, Brad
    Ren, Li
    Risom, Tyler
    Rudolph, Joachim
    Seo, Jeongbeob
    Sturgis, Hillary L.
    Voegtli, Walter C.
    Wen, Zhaoyang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (18) : 5533 - 5537
  • [37] In-Silico Screening-Based Discovery of New Natural eEF2K Inhibitors with Neuritogenic Activity
    Wang, Shu-Qin
    Wang, Xinyu
    Guo, Lingling
    Chen, Xiao-Xia
    Huang, Xiao-Jun
    Zhang, Shiqing
    Ye, Wen-Cai
    Zhang, Xiao-Qi
    Shi, Lei
    Wang, Ying
    Hu, Li-Jun
    ACS MEDICINAL CHEMISTRY LETTERS, 2025, 16 (03): : 475 - 482
  • [38] Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
    Herman, Ariel G.
    Hayano, Miki
    Poyurovsky, Masha V.
    Shimada, Kenichi
    Skouta, Rachid
    Prives, Carol
    Stockwell, Brent R.
    CANCER DISCOVERY, 2011, 1 (04) : 312 - 325
  • [39] Discovery of the oncogenic MDM2, a direct binding target of berberine and a potential therapeutic, in multiple myeloma
    Li, Chuting
    Su, Ru
    Wang, Xiuyuan
    Huang, Guiping
    Liu, Yanjun
    Yang, Juhua
    Yin, Zhao
    Gu, Chunming
    Fei, Jia
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2022, 22 (05) : 1031 - 1041
  • [40] CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors
    Xi, Meiyang
    Chen, Tingkai
    Wu, Chunlei
    Gao, Xiaozhong
    Wu, Yonghua
    Luo, Xiang
    Du, Kui
    Yu, Lemao
    Cai, Tao
    Shen, Runpu
    Sun, Haopeng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 : 77 - 91